IL18 and neoplasm: Because IL-18 primarily amplifies effector cytokine production rather than directly enforcing long-term memory programs, its prolonged or systemic presence can accelerate inflammation-associated exhaustion unless tightly regulated; tumor-localized or CAR-stimulated IL-18 release optimizes antitumor synergy while reducing systemic risks (89–91).